Table 4.
Assesment of C6 tumor growth in mice receiving magnetoliposomes containing or not ω-3 PUFA-EE.
| Type of liposomal preparation injected a) | Mouse b) | Initial size (mm2) c) | Final size (mm2) d) | % increase or decrease tumor size after treatment |
|---|---|---|---|---|
| None, saline | Mouse 1 | 12.72 | 18.87 | +48.35% |
| Mouse 2 | 38.89 | 131.82 | +238.96% | |
| Empty Liposomes | Mouse 5 | 13.46 | 26.92 | +200,00% |
| Mouse 6 | 18.37 | 76.23 | +414,90% | |
| Nanotex Liposomes | Mouse 9 | 15.756 | 27.5 | +74.54% |
| Mouse 10 | 14.473 | 20.212 | +39.65% | |
| Mouse 11 | 8.298 | 13.787 | +66.15% | |
| Nanotex + ω-3 PUFA-EE Liposomes | Mouse 13 | 12.624 | 2.825 | -77.62% |
| Mouse 14 | 6.07 | 0.396 | -93.48% | |
| Mouse 15 | 8.952 | 0.347 | -96.12% | |
| Mouse 16 | 24.377 | 10.179 | -58.24% |
a) Liposomal preparations were administered i.v. through the tail vein fifteen days after C6 cell implantation.
b) Groups containing four mice at the time of treatment initiation were used in all conditions. Only the mice surviving six days after treatment initiation are shown.
c) Tumor size before treatment initiation.
d) Tumor size after six days of treatment.
c,d) Tumor area (mm2) reflects the area including the tumor and peripheral inflammation as detected in coronal cross sections of T2w images obtained before (initial) or six days after (final) treatment.